Study on the release of fenofibrate nanosuspension in vitro and its correlation with in situ intestinal and in vivo absorption kinetics in rats

References

• Lee JJ, Jin YR, Yu JY, et al. Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug. Atherosclerosis 2009;206:375–82
   PubMed Web of Science ®Google Scholar
• Munoz A, Guichard JP, Reginault P. Micronised fenofibrate. Atherosclerosis 1994;110:S45–8
   Web of Science ®Google Scholar
• Adkins JC, Faulds, D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidemia. Drugs 1997;54:615–33
   PubMed Web of Science ®Google Scholar
• Guichard JP, Blouquin P, Qing Y. A new formulation of fenofibrate: suprabioavailable tablets. Curr Med Res Opin 2000;16:134–8
   PubMed Web of Science ®Google Scholar
• Hanafy A, Spahn-Langguth H, Vergnault G, et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Delivery Rev 2007;59:419–26
   PubMed Web of Science ®Google Scholar
• Wang P, Luo Q, Miao Y, et al. Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. Drug Dev Ind Pharm 2012;38:1344–53
   PubMed Web of Science ®Google Scholar
• Rao GC, Kumar MS, Mathivanan N, Rao, ME. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie 2004;59:5–9
   PubMed Web of Science ®Google Scholar
• Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm 2011;409:260–8
   PubMed Web of Science ®Google Scholar
• Li X, Gu L, Xu Y, Wang Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Dev Ind Pharm 2009;35:827–33
   PubMed Web of Science ®Google Scholar
• Wang L, Hao Y, Liu N, et al. Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method. Drug Dev Ind Pharm 2012;38:1381–9
   PubMed Web of Science ®Google Scholar
• Curtet B, Teillaud E, Reginault P. Galenic form of fenofibrate comprising a surfactant [P]. EP: 330532:1989208230. (CA 1990:113: 29260x)
   Google Scholar
• Huo DJ, Deng SH, Li LB, Ji, JB. Studies on the poly(lactic-coglycolic) acid microspheres of cisplatin for lung-targeting. Int J Pharm 2005;289:63–7
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Taniguchi T, Rikyuu K, et al. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res 1994;11:1496–500
   PubMed Web of Science ®Google Scholar
• Doluisio JT, Billups NF, Dittert LW, et al. Drug absorption: an in situ rat gut technique yielding realistic absorption rates. J Pharm Sci 1969;58:1196–200
   PubMed Web of Science ®Google Scholar
• Sinko PJ, Patel NR, Hu P. Site-specific oral absorption of didanosine: in situ characterization and correlation with extent of absorption in vivo. Int J Pharm 1994;109:125–33
   Web of Science ®Google Scholar
• Parvin ZM, Mohammad BJ, Hosniyeh T, et al. Simultaneous determination of naproxen, ketoprofen and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J Pharm Biomed Anal 2005;39:624–30
   PubMed Web of Science ®Google Scholar
• Michel C, Aprahamian M, Defontaine L, et al. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J Pharm Pharmacol 1991;43:1–5
   PubMed Web of Science ®Google Scholar
• United States Pharmacopeia and National Formulary (USP 32 NF 27). In vitro and in vivo evaluation of dosage forms. United States Pharmacopeia Convention; 2009:1088–9
   Google Scholar
• National Pharmacopoeial Committee. Guidance for sustained-release, controlled release and delayed release formulations. Pharmacopoeia of the People’s Republic of China (Appendix XIX D); 2010:201–4
   Google Scholar
• Florence AT. Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discovery Today: Technol 2005;2:75–81
   PubMedGoogle Scholar
• Araujo L, Sheppard M, Löbenberg R, Kreuter, J. Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of the body distribution after suspension in surfactant solutions and in oil vehicles. Int J Pharm 1999;176:209–24
   Web of Science ®Google Scholar
• Neuhoff S, Ungell AL, Zamora I, Artursson P. pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Eur J Pharm Sci 2005;25:211–20
   PubMed Web of Science ®Google Scholar
• Kocbek P, Baumgartner S, Krist J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006;312:179–86
   PubMed Web of Science ®Google Scholar
• Kang M, Kim H, Jeon H, et al. In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system. Drug Dev Ind Pharm 2012;38:587–96
   PubMed Web of Science ®Google Scholar
• Xie Y, Zeng X, Li G, et al. Assessment of intestinal absorption of total flavones of Hippophae rhamnoides L. in rat using in situ absorption models. Drug Dev Ind Pharm 2010;36:787–94
   PubMed Web of Science ®Google Scholar
• Masaoka Y, Tanaka Y, Kataoka M, et al. (2006). Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci 2006;29:240–50
   PubMed Web of Science ®Google Scholar
• Hussain N, Jaitley V, Florence AT. Florence: recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 2001;50:107–42
   PubMed Web of Science ®Google Scholar
• Yuan H, Chen J, Du YZ, et al. Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf B: Biointerfaces 2007;58:157–64
   PubMed Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2005;107:215–28
   PubMed Web of Science ®Google Scholar
• Duchêne D, Ponchel G. Bioadhesion of solid oral dosage forms, why and how? Eur J Pharm Biopharm 1997;44:15–23
   Web of Science ®Google Scholar
• Venkatesan N, Uchino K, Amagase K, et al. Gastrointestinal patch system for the delivery of erythropoietin. J Control Release 2006;111:19–26
   PubMed Web of Science ®Google Scholar